Through the mission an entire ecosystem for services from treatment to critical research will be created in every corner of the country
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
With the launch of QurOne, the brand aims to redefine healthcare in the country with seamless, hassle-free patient care and hyper-coordinated workflows
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
This unique record was made possible by collating hard copies of the books in a structured manner
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
Subscribe To Our Newsletter & Stay Updated
